IP Group invests in drug developer Activiomics

Activiomics, a developer of technologies for transforming the way in which drug biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled, has received investment of more than £500,000 led by IP Group, a developer of intellectual-property-based businesses.

Activiomics’ proprietary technology has broad application in the area of biomarker and drug discovery in a number of disease areas, including oncology and inflammation.

Since its incorporation in February 2010, the company has demonstrated the value of its technology through revenue-generating partnerships with big pharmaceutical companies, including Glaxosmithkline, UCB and Genentech.